uMotif is a clinical trial technology company that provides a platform for patient engagement and data collection, and ActiGraph is a provider of wearable remote monitoring technology. The partnership involves both companies combining their particular expertise to create a solution for clinical research.
ActiGraph played the active role by inviting uMotif to join its ‘accelerant partner program’, which has been designed to advance the use of digital health technologies in clinical development by improving access to raw data streams.
According to the partners, uMotif brings with it a program that delivers more than 90% eCOA/ePRO compliance in both clinical trials and real-world studies.
The company delivers the eCOA and ePRO options via a cloud-based platform, allowing the technology to support the delivery of clinical trials worldwide. For ActiGraph’s part, its wearable technology allows for the capture of clinical-grade actigraphy data.
The plan for the companies is to provide a patient-friendly solution that captures both subjective ePRO and objective device data through ‘a single experience’.
uMotif CEO, Steve Rosenberg, said, “Our eCOA/ePRO solutions combined with ActiGraph’s wearables and science-based algorithms and services are a big step forward in putting patients’ comfort and convenience at the center of research, so we can collect massive amounts of quality data while making their lives a bit easier.”
When explaining the decision to partner together, the companies stated that sponsors are increasingly focused on making trials more patient-centric. The decision to partner together was announced during the annual SCOPE event, which was held from February 6-9, and where decentralized trials had been expected to feature as a major topic of conversation.
For ActiGraph, the agreement with uMotif is the second such agreement in the space of a few months, after it made a similar agreement with Parexel in 2022. Parexel also joined the accelerant partner program, to become the first member.
By joining the program, Parexel gained access to ActiGraph’s wearable devices, as well as services that would allow for the deployment and management of the latter’s digital endpoints.
According to a report conducted in the early stages of the COVID-19 pandemic, the technology behind wearable devices was found to have advanced rapidly, with more pharmaceutical companies interested in utilizing them within clinical trials.